ICR Zytiga Royalty Entitlement

ICR Zytiga Royalty Entitlement Overview

Status Acquired/​Merged
Latest Deal Type Buyout/​LBO
Financing Rounds 1

ICR Zytiga Royalty Entitlement General Information

Description

A portion of the royalty entitlement relating to the sales of Zytiga drug brand. The royalty entitlement of the Zytiga drug brand, which is an abiraterone, is a prescription medicine that is used along with prednisone to treat men with late-stage metastatic prostate cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Primary Industry
Other Business Products and Services
Primary Office
  • London
  • England, United Kingdom
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ICR Zytiga Royalty Entitlement Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ICR Zytiga Royalty Entitlement‘s full profile, request access.

Request a free trial

ICR Zytiga Royalty Entitlement Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ICR Zytiga Royalty Entitlement‘s full profile, request access.

Request a free trial